Oncopeptides AB Total Liabilities

Latest as of December 2025: Skr193.73 Million SEK ≈ $20.85 Million USD

Oncopeptides AB total liabilities. Based on the latest financial reports, Oncopeptides AB (ONCO) has total liabilities worth Skr193.73 Million SEK (≈ $20.85 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Oncopeptides AB to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Oncopeptides AB (2014–2025)

Total liabilities of Oncopeptides AB from 2014 to 2025. This chart illustrates how Oncopeptides AB's total liabilities have evolved over time, based on quarterly financial data. Explore Oncopeptides AB strategic investment ratio to see how much of total assets are deployed in long-term investments.

Oncopeptides AB Competitors by Total Liabilities

The table below lists competitors of Oncopeptides AB ranked by their total liabilities.

Company	Country	Total Liabilities
Great Elm Capital Corp NASDAQ:GECC	USA	$169.56 Million
Trinity Precision Technology Co Ltd TWO:4534	Taiwan	NT$765.80 Million
Satia Industries Limited NSE:SATIA	India	Rs4.52 Billion
Xchanging Solutions Limited NSE:XCHANGING	India	Rs1.27 Billion
MediciNova Inc NASDAQ:MNOV	USA	$3.61 Million
ABITARE IN S.P.A. F:1BN	Germany	€266.96 Million
Simply Better Brands Corp V:SBBC	Canada	CA$13.36 Million
Hyundai Everdigm Corp KQ:041440	Korea	₩127.88 Billion

Liability Composition Analysis (2014–2025)

This chart breaks down Oncopeptides AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ONCO asset base.

Liquidity & Leverage Metrics

Oncopeptides AB Total Liabilities Ratios Explained

Oncopeptides AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	2.63	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-3.29	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	1.44	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Oncopeptides AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Oncopeptides AB (2014–2025)

The table below shows the annual total liabilities of Oncopeptides AB from 2014 to 2025.

Year	Total Liabilities	Change
2025-12-31	Skr193.73 Million ≈ $20.85 Million	+2.01%
2024-12-31	Skr189.91 Million ≈ $20.44 Million	+4.58%
2023-12-31	Skr181.60 Million ≈ $19.54 Million	+99.49%
2022-12-31	Skr91.03 Million ≈ $9.80 Million	-60.16%
2021-12-31	Skr228.51 Million ≈ $24.59 Million	-38.22%
2020-12-31	Skr369.86 Million ≈ $39.80 Million	+88.25%
2019-12-31	Skr196.47 Million ≈ $21.14 Million	+52.66%
2018-12-31	Skr128.70 Million ≈ $13.85 Million	+108.19%
2017-12-31	Skr61.82 Million ≈ $6.65 Million	+111.01%
2016-12-31	Skr29.30 Million ≈ $3.15 Million	+318.39%
2015-12-31	Skr7.00 Million ≈ $753.53K	+26.91%
2014-12-31	Skr5.52 Million ≈ $593.73K	--

About Oncopeptides AB

ST:ONCO Sweden Biotechnology

Market Cap

$69.81 Million

Skr648.71 Million SEK

Market Cap Rank

#20402 Global

#362 in Sweden

Share Price

Skr1.70

Change (1 day)

+2.78%

52-Week Range

Skr1.27 - Skr5.80

All Time High

Skr343.59